Invited letter to the editor on the editorial on “Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy”

It is with great interest that we took notice of the expert knowledge on staging of non-small cell lung cancer (NSCLC) and the implications on adjuvant chemotherapy expressed in the two invited editorials on our previously published article entitled “Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy” (1).